<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04066491</url>
  </required_header>
  <id_info>
    <org_study_id>MS200647_0055</org_study_id>
    <secondary_id>2019-001992-35</secondary_id>
    <nct_id>NCT04066491</nct_id>
  </id_info>
  <brief_title>Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) in Participants With 1L Biliary Tract Cancer (BTC)</brief_title>
  <official_title>A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono Research &amp; Development Institute, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck KGaA, Darmstadt, Germany</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study consists of an open-label, safety run-in part and a randomized, double-blind,
      placebo-controlled Phase 2/3 part. In the Phase 2/3 part, the study will evaluate whether
      bintrafusp alfa in combination with the current standard of care (SoC) (gemcitabine plus
      cisplatin) improves overall survival (OS) in chemotherapy and immunotherapy-na√Øve
      participants with locally advanced or metastatic BTC compared to placebo, gemcitabine and
      cisplatin.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">July 24, 2023</completion_date>
  <primary_completion_date type="Anticipated">November 24, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety Run-in Part: Number of Participants with Dose-Limiting Toxicities (DLTs) During the DLT Evaluation Period</measure>
    <time_frame>Day 1 up to Day 21 of Cycle 1 (each Cycle is of 21 days)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Double-blinded Part: Overall Survival (OS)</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Treatment-Related Adverse Events</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Number of Participants with Abnormalities (Grade &gt;= 3) in Laboratory Tests</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded: Confirmed Objective Response (COR) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Assessed by Investigator</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Duration of Response (DOR) Assessed From Complete Response (CR) or Partial Response (PR) According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator or Death</measure>
    <time_frame>Time from CR or PR up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Durable Response of at Least 6 Months According to Response Evaluation Criteria In Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Number of Participants with Treatment-Emergent Adverse Events (TEAEs), Treatment Related Adverse Events and Adverse Events of Special Interest (AESI)</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Serum Concentration Observed Immediately at the End of Infusion (Ceoi) of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Serum Concentration Observed Immediately Before Next Dosing (Ctrough) of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Area Under Serum Concentration-Time Curve (AUC0-t) From Time Zero to The Last Sampling Time of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1 and Day 2, Week 2 Day 8, Week 3 Day 15, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Area Under Serum Concentration-Time Curve from Time Zero Extrapolated to Infinity (AUC0-inf) of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1 and Day 2, Week 2 Day 8, Week 3 Day 15, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Maximum Observed Serum Concentration (Cmax) of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1 and Day 2, Week 2 Day 8, Week 3 Day 15, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Time to Reach Maximum Observed Serum Concentration (Tmax) of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1 and Day 2, Week 2 Day 8, Week 3 Day 15, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety Run-in Part: Apparent Terminal Half-Life (t1/2) of Bintrafusp alfa</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 1 Day 1 and Day 2, Week 2 Day 8, Week 3 Day 15, Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Immunogenicity as measured by Anti-drug Antibodies Concentration</measure>
    <time_frame>Pre-dose, 30 minutes post-dose at Week 4 Day 22, Week 7 Day 43, Week 13 Day 85, Week 19 Day 127, Week 25 Day 169 and every 12 week from Week 25 approximately up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Double-blinded Part: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 Assessed by Investigator</measure>
    <time_frame>First dose of study intervention up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">512</enrollment>
  <condition>Biliary Tract Cancer</condition>
  <condition>Cholangiocarcinoma</condition>
  <condition>Gallbladder Cancer</condition>
  <arm_group>
    <arm_group_label>Safety Run-In Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blinded Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Double-blinded Part: Placebo + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bintrafusp alfa</intervention_name>
    <description>Participants will receive Bintrafusp alfa intravenously at a dose of 2400 milligram (mg) once every 3 weeks (Q3W) until confirmed disease progression, death, unacceptable toxicity, study withdrawal or for 2 years after the first onset of Complete Response (CR).</description>
    <arm_group_label>Double-blinded Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Safety Run-In Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
    <other_name>M7824</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Participants will receive Bintrafusp alfa matched Placebo intravenously once every 3 weeks (Q3W) until confirmed disease progression, death, unacceptable toxicity, study withdrawal or for 2 years after the first onset of CR.</description>
    <arm_group_label>Double-blinded Part: Placebo + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine will be received intravenously at a dose of 1000 milligram per meter square (mg/m^2) on Day 1 and Day 8 of 21- day cycle, for 8 cycles every 3 weeks (Q3W).</description>
    <arm_group_label>Double-blinded Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Double-blinded Part: Placebo + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Safety Run-In Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>Cisplatin will be received intravenously at a dose of 25 mg/m^2 on Day 1 and Day 8 of 21-day cycle, for 8 cycles every 3 weeks (Q3W).</description>
    <arm_group_label>Double-blinded Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Double-blinded Part: Placebo + Gemcitabine + Cisplatin</arm_group_label>
    <arm_group_label>Safety Run-In Part: Bintrafusp alfa + Gemcitabine + Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are participants with histologically or cytologically confirmed locally advanced or
             metastatic BTC

          -  Participants must have available tumor tissue (primary or metastatic) (archival or
             fresh biopsies) before the first administration of study treatment

          -  At least 1 measurable lesion according to RECIST 1.1

          -  Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 at study
             entry and at Week 1, Day 1 prior to dosing

          -  Life expectancy of &gt;= 12 weeks, as judged by the Investigator

          -  Adequate hematological function, hepatic function, renal function, coagulation
             function as defined in the protocol

          -  Hepatitis B virus (HBV) deoxyribonucleic acid (DNA) positive participants must be
             treated and on a stable dose of antivirals

          -  Other protocol defined inclusion criteria could apply

        Exclusion Criteria:

          -  Previous and/or intercurrent cancers

          -  Receipt of any organ transplantation, including allogeneic stem-cell transplantation,
             but with the exception of transplants that do not require immunosuppression

          -  Participants with symptomatic central nervous system (CNS) metastases

          -  Significant acute or chronic infection including known history of positive test for
             human immunodeficiency virus (HIV), active tuberculosis, uncontrolled biliary
             infection and active bacterial or fungal infection requiring systemic therapy

          -  Active autoimmune disease that might deteriorate when receiving an immunostimulatory
             agent

          -  History of or concurrent interstitial lung disease

          -  History of hypersensitivity reactions to bintrafusp alfa, anaphylaxis, or recent
             (within 5 months) uncontrolled asthma, cardiovascular/cerebrovascular disease

          -  Chronic obstructive pulmonary disease exacerbation or other respiratory illness
             requiring hospitalization or precluding study therapy within 30 days before
             randomization

          -  Prior therapy with any antibody/drug targeting T-cell coregulatory proteins (immune
             checkpoints)

          -  Other protocol defined exclusion criteria could apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Responsible</last_name>
    <role>Study Director</role>
    <affiliation>Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Medical Information</last_name>
    <phone>888-275-7376</phone>
    <email>eMediUSA@emdserono.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Communication Center</last_name>
    <phone>+49 6151 72 5200</phone>
    <email>service@emdgroup.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ironwood Cancer &amp;amp; Research Centers - Chandler II</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>shtivelband@ironwoodcrc.com</email>
    </contact>
    <investigator>
      <last_name>Mikhail I Shtivelband</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Banner MD Anderson Cancer Center</name>
      <address>
        <city>Gilbert</city>
        <state>Arizona</state>
        <zip>85234</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>borad.mitesh@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mitesh J Borad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Beverly Hills Cancer Center</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>eligabayan@bhcancercenter.com</email>
    </contact>
    <investigator>
      <last_name>Afshin E Gabayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic in Florida - Department of Neurology</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mody.kabir@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Kabir Mody</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Medical Center</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center at John Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>nazad2@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Nilofer Azad</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Rochester</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mahipal.amit@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Amit Mahipal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center Research Institute, Inc. - University of Kansas Cancer Center/Bloch Pavilion</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Methodist Transplant Physicians</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>parvezmantry@mhd.com</email>
    </contact>
    <investigator>
      <last_name>Parvez Mantry</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center - Unit 429</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sslee1@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Sunyoung S Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Renovatio Clinical - CENTRAL SITE</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Gastroenterologia Dr. Carlos Bonorino Udaondo</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>mendezdoc@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Guillermo Mendez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Metabolicas (IDIM)</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>juane_cundom@yahoo.com.ar</email>
    </contact>
    <investigator>
      <last_name>Juan Esteban Cundom</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Medico Especializado Alexander Fleming</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>juanmanuel.oconnor@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan O¬¥Connor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Oncologico Riojano Integral (CORI)</name>
      <address>
        <city>La Rioja</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sanatorio El Carmen</name>
      <address>
        <city>Salta</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>ga255538@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Gerardo Francisco Arroyo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro Medico San Roque S.R.L.</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>josezarba@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Juan Jose Zarba</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion ARS Medica</name>
      <address>
        <city>San Salvador de Jujuy</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Blacktown Hospital - PARENT</name>
      <address>
        <city>Blacktown</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>adnan.nagrial@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Adnan Nagrial</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icon Cancer Care South Brisbane</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>paul.vasey@icon.team</email>
    </contact>
    <investigator>
      <last_name>Paul Vasey</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Epworth Freemasons</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sumitra.ananda@mh.org.au</email>
    </contact>
    <investigator>
      <last_name>Sumitra Ananda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Monash Health</name>
      <address>
        <city>Victoria</city>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>eva.segelov@monash.edu</email>
    </contact>
    <investigator>
      <last_name>Eva Segelov</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>IC la serena Research</name>
      <address>
        <city>La Serena</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luisa Morales</last_name>
      <email>luisa.morales@iclsr.cl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Health &amp; Care - Prosalud Montes y Orlandi Ltda.</name>
      <address>
        <city>Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>pvsalman@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Pamela Salman Boghikian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaci√≥n Cl√≠nica Bradford Hill</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>cirojas@bradfordhill.cl</email>
    </contact>
    <investigator>
      <last_name>Carlos Rojas</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Cl√≠nico Universidad de Chile</name>
      <address>
        <city>Santiago</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>luismavillanueva@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Luis Villanueva Olivares</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Instituto Clinico Oncologico del Sur (ICOS)</name>
      <address>
        <city>Temuco</city>
        <country>Chile</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>eduardoyanez.icos@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Eduardo Ya√±ez Ruiz</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aichi Cancer Center Hospital</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi-Ken</state>
        <zip>464-8681</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>kuwa_tak@aichi-cc.jp</email>
    </contact>
    <investigator>
      <last_name>Takamichi Kuwahara</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chiba Cancer Center</name>
      <address>
        <city>Chiba-shi</city>
        <state>Chiba-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ksudo@chiba-cc.jp</email>
    </contact>
    <investigator>
      <last_name>Kentaro Sudo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital East</name>
      <address>
        <city>Kashiwa-shi</city>
        <state>Chiba-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>masikeda@east.ncc.go.jp</email>
    </contact>
    <investigator>
      <last_name>Masafumi Ikeda</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NHO Kyushu Cancer Center - Dept of Gastroenterology/Hepatology/Pancreatology</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka-Ken</state>
        <zip>811-1395</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>massfullfuru@yahoo.co.jp</email>
    </contact>
    <investigator>
      <last_name>Masayuki Furukawa</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kanagawa Cancer Center</name>
      <address>
        <city>Yokohama-shi</city>
        <state>Kanagawa-Ken</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>uenom@kcch.jp</email>
    </contact>
    <investigator>
      <last_name>Makoto Ueno</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kindai University Hospital</name>
      <address>
        <city>Osakasayama-shi</city>
        <state>Osaka-Fu</state>
        <zip>589-8511</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>m-kudo@med.kindai.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Masatoshi Kudo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center Hospital - Dept of Hepatobiliary and Pancreatic Oncology</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cmorizan@ncc.go.jp</email>
    </contact>
    <investigator>
      <last_name>Chigusa Morizane</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cancer Institute Hospital of JFCR - Dept of Hepato,Biliary and Pancreatic Medicine</name>
      <address>
        <city>Koto-ku</city>
        <state>Tokyo-To</state>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lastnamefirstname@email.jp</email>
    </contact>
    <investigator>
      <last_name>Takashi Sasaki</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kyorin University Hospital</name>
      <address>
        <city>Mitaka-shi</city>
        <state>Tokyo-To</state>
        <zip>181-8611</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jfuruse@ks.kyorin-u.ac.jp</email>
    </contact>
    <investigator>
      <last_name>Junji Furuse</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Osaka City University Hospital</name>
      <address>
        <city>Osaka-shi</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shoji Kubo</last_name>
      <email>m7696493@msic.med.osaka-cu.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>jwkim@snubh.org</email>
    </contact>
    <investigator>
      <last_name>Jin won Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital - Department of Internal Medicine (Rheumatology)</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ryhw001@naver.com</email>
    </contact>
    <investigator>
      <last_name>Hyewon Ryu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>changhoon.yoo.amc@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Changhoon Yoo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>yhk0215@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Yeul Hong Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>sachoh@korea.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Sang Cheul Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>oncopark@skku.edu</email>
    </contact>
    <investigator>
      <last_name>Joon Oh Park</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>ohdoyoun@snu.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Do-Youn Oh</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>cklee512@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Choong-kun Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>angelamd@catholic.ac.kr</email>
    </contact>
    <investigator>
      <last_name>Myung-Ah Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im.M.Sklodowskiej Curie</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Wieslaw Bal</last_name>
      <email>balwieslaw@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pratia</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bozena Cybulska-Stopa</last_name>
      <email>bcybulskastopa@vp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Onkologii im. Marii Sk≈Çodowskiej-Curie - Pa≈Ñstwowy Instytut Badawczy</name>
      <address>
        <city>Warszawa</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lucjan Wyrwicz</last_name>
      <email>lucjanwyrwicz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ETG Zamosc</name>
      <address>
        <city>Zamosc</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Teresa Sosnowska</last_name>
      <email>teresa.anna.sosnowska@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO l¬¥Hospitalet - Hospital Duran i Reynals</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>blaquente@iconcologia.net</email>
    </contact>
    <investigator>
      <last_name>Berta Laquente Saez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic i Provincial de Barcelona - Servicio de Oncologia</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>sauri@clinic.cat</email>
    </contact>
    <investigator>
      <last_name>Tamara Sauri Nadal</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari Vall d'Hebron - Dept of Oncology</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>hverdaguer@vhio.net</email>
    </contact>
    <investigator>
      <last_name>Helena Verdaguer Mata</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcantara - Servicio de Oncologia</name>
      <address>
        <city>Caceres</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jorgemluengo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jorge Mu√±oz Luengo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofia - Dept of Oncology</name>
      <address>
        <city>Cordoba</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>magespanya@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Auxiliadora M Gomez Espana</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Mara√±on - Servicio de Oncologia Medica</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>andresmunmar@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Andres Mu√±oz Martin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Clinico San Carlos - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jsastrev@salud.madrid.org</email>
    </contact>
    <investigator>
      <last_name>Javier Sastre Valera</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario HM Madrid Sanchinarro - Servicio de Oncologia</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>acubillo@hmhospitales.com</email>
    </contact>
    <investigator>
      <last_name>Antonio Cubillo Gracian</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Valencia - Servicio de Hematologia y Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>derope@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>Desamparados Roda Perez</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politecnic La Fe - Servicio de Oncologia Medica</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>diaz_rob@gva.es</email>
    </contact>
    <investigator>
      <last_name>Roberto Diaz Beveridge</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>kuerten@adm.cgmh.org.tw</email>
    </contact>
    <investigator>
      <last_name>Tai-Jan Chiu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>lybai6@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Li-Yuan Bai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>tylee@vghtc.gov.tw</email>
    </contact>
    <investigator>
      <last_name>Teng-Yu Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cheng Kung University Hospital</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>yencj@mail.ncku.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Chia-Jui Yen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>chihhunghsu@ntu.edu.tw</email>
    </contact>
    <investigator>
      <last_name>Chih-Hung Hsu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>mhchen9@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Ming-Huang Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital, Linkou</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <email>jschen1101@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jen-Shi Chen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Chile</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>https://www.intrapidclinicaltrials.com/en</url>
    <description>INTR@PID Clinical Trial Program</description>
  </link>
  <link>
    <url>https://clinicaltrials.emdgroup.com/en/trial-details/?id=MS200647_0055</url>
    <description>Trial Awareness and Transparency website</description>
  </link>
  <link>
    <url>https://medical.emdserono.com/en_US/home.html</url>
    <description>US Medical Information website, Medical Resources</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>August 22, 2019</study_first_submitted>
  <study_first_submitted_qc>August 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2019</study_first_posted>
  <last_update_submitted>June 15, 2020</last_update_submitted>
  <last_update_submitted_qc>June 15, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic Biliary Tract Cancer</keyword>
  <keyword>Cholangiocarcinoma</keyword>
  <keyword>Gallbladder Cancer</keyword>
  <keyword>Ampullary cancer</keyword>
  <keyword>M7824</keyword>
  <keyword>Bintrafusp alfa</keyword>
  <keyword>Transforming growth factor-beta</keyword>
  <keyword>Programmed death-ligand 1</keyword>
  <keyword>INTR@PID</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
    <mesh_term>Biliary Tract Neoplasms</mesh_term>
    <mesh_term>Gallbladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

